Serum Institute of India to Produce Additional 100 Million COVID-19 Vaccine Doses for India

New Delhi: The Serum Institute of India (SII) today announced that it would produce upto an additional 100 million COVID-19 vaccine doses for India in 2021.

A further collaboration among the SII, Gavi and the Bill & Melinda Gates Foundation will accelerate the manufacture and delivery of up to 100 million doses of safe and effective COVID-19 vaccines for India and low-and middle-income countries (LMICs) as part of the Gavi COVAX AMC, a mechanism within the COVAX Facility, the company said in a statement.

This brings the total number of vaccine doses to be covered by the partnership between SII, Gavi, and the Gates Foundation to an aggregate of up to 200 million doses, following the initial agreement for up to 100 million doses announced in August, it added.

The arrangement again provides an option to secure additional doses if the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator sees a need for it.
The collaboration will provide upfront capital to SII to help it increase manufacturing capacity now so that, once a vaccine, or vaccines, gains regulatory approval and WHO Prequalification, doses can be distributed at scale to LMICs as part of the Gavi COVAX AMC mechanism as early as the first half of 2021.

“The collaboration further bolsters up our fight against COVID-19! Through the avid support of Gavi and the Bill & Melinda Gates Foundation, we will now manufacture and deliver up to an additional 100 million doses of immunogenic and safe-proven future COVID-19 vaccines to India and low-and middle-income countries in 2021,” said Adar Poonawalla, CEO of Serum Institute of India.